The Day In Review: Amgen Disappoints After The Bell

January 25, 2007 – After the closing bell, Amgen reported Q4 earnings that were 5 cents below expectations; Biogen Idec began a Phase III study of a cancer drug in patients with non-Hodgkin’s lymphoma; Oculus priced its IPO at $8 per share, the bottom of its lowered range; Vion Pharma will fully enroll a Phase II test of Cloretazine in leukemia because early results were good; BioCryst began a Phase II trial of peramivir, its seasonal/pandemic flu treatment; Schering-Plough received some high-profile exposure on its anti-fungal drug Noxafil; Cardinal Health will sell its contract manufacturing business for $3.3 billion; and Cytori received 510(K) clearance for a device that processes stem cells from adipose tissue. The Centient Biotech 200™ fell 33 points to 4065, a loss of .82%. More details...